Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214857 · ClinicalTrials.gov registry record
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,385
- Enrollment target
NCT07214857 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,385 participants.
The verdict
NCT07214857 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,385 participants
- Enrollment target
Study Summary
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and Nutrition Examination Survey (NHANES) data and inclisiran eligibility criteria from ongoing clinical trials as well as to estimate the number of preventable ASCVD events based on expected risk reductions from the degree of low-density lipoprotein cholesterol (LDL-C) lowering expected from inclisiran. This study used data from the US NHANES 2011-2020 surveys. NHANES is a national survey which collects medical history, laboratory, and medication information from participants of all ages.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,385 participants |
| Start Date | 2024-03-29 |
| Est. Completion | 2024-10-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07214857
The ClinicalTrials.gov registry entry for NCT07214857 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07214857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07214857 about?
NCT07214857 is a clinical study titled "Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States". The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and Nutrition Examination Survey (NHANES) data and inclisiran eligibility cr...
What is the current status of trial NCT07214857?
This trial is currently completed. The enrollment target is 1,385 participants. The study started on 2024-03-29. Estimated completion is 2024-10-09.
Who is sponsoring clinical trial NCT07214857?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.